Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.
Catalent Cell & Gene Therapy will provide drug substance manufacturing for the University of Oxford’s adenovirus vector-based vaccine at Catalent’s Harmans, Maryland gene therapy manufacturing facility.
Catalent today announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022.
Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.
Catalent Cell & Gene Therapy will provide drug substance manufacturing for the University of Oxford’s adenovirus vector-based vaccine at Catalent’s Harmans, Maryland gene therapy manufacturing facility.
